Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability‐High End‐Stage Cancers and Poor Performance Status Related to High Disease Burden

BACKGROUND: Few real‐world series on the efficacy and safety of anti‐programmed cell death protein‐1(PD‐1)/programmed death ligand‐1(PD‐L1)–based therapy are available in molecularly unselected patients with poor performance status (PS) and specific types of advanced cancers, because such population...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncologist
Main Authors: Pietrantonio, Filippo, Loupakis, Fotios, Randon, Giovanni, Raimondi, Alessandra, Salati, Massimiliano, Trapani, Dario, Pagani, Filippo, Depetris, Ilaria, Maddalena, Giulia, Morano, Federica, Corallo, Salvatore, Prisciandaro, Michele, Corti, Francesca, Guarini, Vincenzo, Bocconi, Alessandro, Marra, Antonio, Belli, Carmen, Spallanzani, Andrea, Fassan, Matteo, Lonardi, Sara, Curigliano, Giuseppe, Fucà, Giovanni, Di Bartolomeo, Maria, de Braud, Filippo
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley & Sons, Inc. 2020
נושאים:
Immuno‐Oncology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485362/
https://ncbi.nlm.nih.gov/pubmed/32369650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0014
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים